Abbott Laboratories Aktie News

Abbott Laboratories (ABT) earns a buy rating for its operational resilience, robust fundamentals, and strong dividend growth despite headwinds. ABT delivered double-digit EPS growth, solid Medical Devices performance, and increased its dividend by 7%, demonstrating ongoing financial strength. The pending $21B Exact Sciences acquisition is expected to be accretive, further strengthening ABT's gr...

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbot...

CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition.

Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.

Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 408th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%.

The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.